|
|
Volumn 27, Issue 3, 2009, Pages 215-217
|
|
Report blames NICE for hastening decline of UK biotech
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
BORTEZOMIB;
RANIBIZUMAB;
SORAFENIB;
SUNITINIB;
TEMSIROLIMUS;
BIOTECHNOLOGY;
BREAST CANCER;
COST BENEFIT ANALYSIS;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
FUNDING;
HEALTH CARE ORGANIZATION;
HUMAN;
KIDNEY CANCER;
MULTIPLE MYELOMA;
NOTE;
PRIORITY JOURNAL;
REIMBURSEMENT;
TREATMENT RESPONSE;
UNITED KINGDOM;
WORLD HEALTH ORGANIZATION;
ADULT;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
BIOTECHNOLOGY;
BREAST NEOPLASMS;
COST-BENEFIT ANALYSIS;
DECISION MAKING, ORGANIZATIONAL;
DRUG APPROVAL;
FEMALE;
GOVERNMENT AGENCIES;
GREAT BRITAIN;
HUMANS;
NATIONAL HEALTH PROGRAMS;
RECEPTOR, ERBB-2;
TECHNOLOGY ASSESSMENT, BIOMEDICAL;
|
|
EID: 62149145393
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0309-215 Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|
